Northeast Pharmaceutical released its 2026 half-year report, showing first-half net profit attributable to the parent of 83.86 million yuan, down 35.1% year on year. Operating revenue was 3.333 billion yuan, down 13.5% year on year. Net profit attributable to the parent after deducting non-recurring items was 57.24 million yuan, down 35.9% year on year. Net operating cash flow was negative 73.96 million yuan, down 170.4% year on year. In the second quarter, operating revenue was 1.33 billion yuan, down 30.4% year on year, and net profit attributable to the parent was 57.23 million yuan, down 38.4% year on year. As of the end of the second quarter, the company's total assets were 13.578 billion yuan, up 5.3% from the end of the previous year, and net assets attributable to the parent were 5.534 billion yuan, up 0.1% from the end of the previous year.
Northeast Pharmaceutical Group Co LtdFirst-half net profit attributable to parent fell 35.1% to 83.86 million yuan, with revenue down 13.5% and operating cash flow negative.
